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Abstract 
Background 
The influence of obesity on outcome following total hip replacement (THR) is unclear. 
Restriction to THR on the basis of body mass index (BMI) has been suggested. The purpose 
of this study was to assess the influence of BMI on the risk of revision and 90-day mortality. 
Methods 
This study is a population-based longitudinal cohort study of the National Joint Registry 
(NJR). Using data recorded from April 2003 to December 2015, linked to Office for National 
Statistics data, we ascertained revision and 90-day mortality rates following primary THR by 
BMI category. The probability of revision was estimated using Kaplan-Meier methods. 
Associations between BMI, revision and mortality were explored using adjusted Cox 
proportional hazards regression models. 
Results 
 
We investigated revision and 90-day mortality in 415,598 and 413,741 operations, 
respectively. Each dataset accounts for approximately 58% of the total number of recorded 
operations in the NJR. 38% of patients were obese. At 10 years, obese class III patients had 
the highest cumulative probability of revision (6.7%;95%CI:5.5,8.2), twice that of the 
underweight group (3.3%;95%CI:2.2,4.9). When adjusted for age, gender, ASA grade, year 
of operation, indication and type of operation and compared to normal BMI, significantly 
higher hazard ratios for revision were observed in obese class I 
(1.14;95%CI:1.07,1.22;p<0.0001), II (1.30;95%CI:1.19,1.40;p<0.0001) and III 
(1.43;95%CI:1.27,1.61;p<0.0001) patients. 
Underweight patients had a substantially higher 90-day mortality (1.17%;95%CI:0.9,1.6) 
than normal. The hazard ratio of 90-day mortality was significantly higher in underweight 
(2.09;95%CI:1.51,2.89;p<0.0001) and significantly lower in overweight 
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(0.70;95%CI:0.61,0.81;p<0.0001), obese class I (0.69;95%CI:0.59,0.81;p<0.0001), and II 
(0.79;95%CI:0.63,0.98;p=0.049) patients. 
Conclusions 
 
Although revision rates in the long term following THR are higher in obese patients, the rates 
remained acceptable by contemporary standards and are balanced by a lower risk of 90-day 
mortality. 
Level of Evidence: Level II 
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Introduction 
 
The outcome of total hip replacement (THR) is assessed by various metrics1; including 
revision2,3 and increases in mortality above background population rates4. 
The prevalence of obesity (body mass index (BMI) ≥30 kg.m-2) in the United States of 
America (USA) increased from 12% in 19915 to 38% in 20146 and in the United-Kingdom 
(UK) from 15% in 1993 to 27% in 20157. Obesity is associated with an increased risk of 
developing osteoarthritis (OA) 8 and undergoing THR9. 
Several studies have investigated the effect of BMI on revision risk; however these studies do 
not all agree. Studies of primary care databases and national registries from the UK and New 
Zealand ranging from 5,357 to 63,162 patients have shown variable associations between 
increased BMI and the risk of revision10-12. Other large cohorts and regional registry studies 
ranging from 1,421 to 27,571 patients have shown no significant association between BMI 
and revision13-16. 
Studies of BMI and mortality at 30-days, 90-days have shown mixed results. Four registry 
studies in the USA17-20 and a single center study in the UK21 (n=2,000 to 432,841), showed 
no significant association. Registry studies based in Denmark and the UK (n=34,000 and 
410,000) have shown a protective effect of being overweight on 30- and 90-day mortality4,22. 
One small Finnish study showed a protective effect of increasing BMI on mortality risk23. 
The association between obesity, measured by BMI, with revision and mortality following 
THR is unclear. This is a contentious issue in settings such as the NHS24-26 and the USA27 
due to the proposed restriction of THR according to BMI, although there is currently no 
restriction by the NHS28. Using data from the National Joint Registry for England, Wales 
Northern Ireland and the Isle of Man (NJR), we aim to investigate the association between 
BMI, the risk of revision surgery up to 11-years and risk of 90-day mortality. 
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Materials and Methods 
 
Data was prospectively collected by the NJR in England and Wales from April 1, 2003 to 
December 31, 2015. Data was mandatorily collected in the private sector from inception, and 
in the public sector from 2011. A recent national audit of data entered into the NJR in 2014 
and 2015 estimated data capture of 95% for primary THA and 91% for revision THA. Date 
of death was provided by the Office for National Statistics. 
BMI was recorded for the first time in April, 2004 with version 2 of the NJR Minimum Data 
Set (MDS) data collection form, data collected before that date were therefore excluded. In 
revision analyses, procedures were also excluded for the following reasons: 1) implausible 
(<10kg/m2 or >60 kg/m2) or missing BMIs; 2) missing age, gender, NHS number; 3) 
unspecified hip replacement type, operation indication, or bearing type; 4) patients receiving 
THR due to trauma. In mortality analyses, for patients undergoing same-day bilateral 
procedures, one of the two procedures was randomly excluded (figure 1). 
The primary exposure was obesity defined using the BMI, classified according to World 
Health Organisation criteria: underweight (10-18.5 kg/m2); normal (19-24 kg/m2); 
overweight (25-29 kg/m2); obese class I (30-34 kg/m2); obese class II (35-39 kg/m2); and 
obese class III (40-60 kg/m2). The primary outcomes were revision following primary THR 
and mortality within 90-days. Patients had a potential maximum 11.75 years follow-up. 
Confounding variables included; age at primary (grouped [<55], [55-59], [60-64], [65-69], 
[70- 74], [75-79], [≥80] years); gender; American Society of Anesthesiologists (ASA) 
physical status classification (grouped [P1], [P2], [P3], [P4-P5]); year of primary THR 
([2004- 2006], [2007-2009], [2010-2012], [2013-2015]; type of THR and fixation (cemented, 
uncemented, hybrid, reverse hybrid and resurfacing) and operation indication ( OA, OA and 
other reason/(s) or other reason/(s)). 
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Following application of the above criteria, the exposure and confounders had no missing 
values. 
To describe continuous variables we used medians and interquartile ranges (IQR), and for 
categorical variables frequencies and percentages. 
Kaplan-Meier failure estimates were plotted to describe revision up to 11.75-years and 
mortality up to 90-days. Time zero was considered the date of the operation, patients exited 
after the first failure was observed, patients were censored upon death and administratively 
censored on December 31, 2015. Where the numbers at risk in subgroups fell below 100 
beyond 10-years follow-up, the 10-year results are presented to provide reasonable estimates 
of the 95% confidence intervals (CI). Log-rank tests were used to compare groups. 
The association between BMI, revision and mortality were explored using Cox ‘proportional 
hazards’ regression models. Multivariable analyses were used to investigate the effect of 
confounding. Models investigating revision were sequentially adjusted: Revision Model 
(RM)1 univariate model; RM2 adjusted for age and gender; RM3 further adjusted for ASA 
and year of primary operation; RM4 further adjusted for fixation type and indication for 
operation. Models investigating mortality were sequentially adjusted: Mortality Model 
(MM)1 univariate model; MM2 adjusted for age and gender; MM3 uses baseline 
stratification by the reason for operation to allow for non-proportionality; MM4 further 
adjusted for ASA and year of primary operation. 
Hazard rate ratios (HR), 95% CIs and p-values are reported. Proportional hazard assumptions 
were investigated graphically using log-log plot of the survival function. 
Analyses were performed with Stata 14.2 (Stata Statistical Software: v.14. College Station, 
TX: StataCorp LP). 
 
 
Sensitivity analyses 
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Two models were fitted to investigate the interaction between BMI and age in revision 
(RM5) and mortality (MM5). Likelihood ratio tests were used to detect significance. 
All analyses were repeated using a competing risk framework, the cumulative incidence 
function instead of 1-KM, and a Fine-Gray model instead of Cox models. In addition, cubic 
splines models were fitted and compared with the Cox models. 
Missing Data 
 
We compared demographic characteristics of procedures of complete and incomplete BMI to 
investigate the potential for systematic biases, and restricted analyses to data collected after 
2007 where BMIs were more complete. 
Source of Funding 
 
*** Blinded by JBJS *** 
 
 
Results 
 
From April 1, 2003 to December 31, 2015, 796,636 primary hip replacements were recorded2. 
Following the exclusion criteria, 415,598 and 413,741 procedures were available to investigate 
revision and 90-day mortality respectively (figure 1), with a maximum follow up of 11.75- 
years. Each cohort accounted for approximately 58% of the total number of operations (table 
1); cases with BMI available are representative of the whole cohort, the only disparity being in 
the year of primary, which is accounted for in our modelling. 
Descriptive statistics were extracted using the revision dataset (n=415,598). 59% of THRs 
were performed in females. Males were slightly younger than females (table 2). 62% of 
patients receiving THA were non-obese (BMI <30 kg/m2), and the majority of obese patients 
(BMI ≥30 kg/m2) were class I. Females were more prevalent in every BMI category (table 3). 
Low ASA grades were more frequent in underweight, normal and overweight patients, while 
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higher ASA grades were similar. The type of hip replacement did not vary depending on the 
BMI. 
Figure 2 illustrates the cumulative probability of revision surgery. Increasing levels of obesity 
were associated with an increased probability of revision (table 4). Patients classified as 
obese class III had a 6.7% (95%CI:5.5,8.2) probability of revision at 10 years after THR 
compared to 3.3% (95%CI:2.2,4.9) for underweight patients (figure 3). 
Figure 4 illustrates the probability of 90-day mortality; a log-rank test indicated a significant 
difference between BMI categories, p<0.0001. 90-day mortality was very low for patients in 
all groups (table 5). Underweight patients had a substantially higher probability of 90-day 
mortality (1.2% 95%CI:0.9,1.6) compared to other groups (figure 5). 
Table 6 presents the Cox ‘proportional hazards’ regression analysis for revision. RM4 shows 
that obese class I, II and III patients are 14%, 30% and 43% respectively more likely to 
undergo revision than normal BMI patients (table 6). No significant difference was found 
between the hazard ratios of the other BMI classes, while there was a trend showing that 
underweight patients were 16% less likely, and overweight patients no more likely, to 
undergo revision than normal BMI patients (table 6). 
Table 7 presents the association between BMI and mortality. MM1 to 4 indicate strong 
evidence that underweight patients have higher and overweight or obese class I have lower 
90-day mortality rates, compared to normal BMI patients. MM4 shows that the mortality rate 
of underweight patients is 109% greater than normal BMI patients. Patients classified as 
either overweight or obese class I are approximately 30% less likely to die within 90-days of 
surgery, while obese classes II and III are 21% and 27% respectively less likely to die 
compared with a normal BMI (table 7). Proportional hazards assumptions were satisfied for 
all the models. 
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A greater proportion of underweight patients were revised for periprosthetic fracture and 
adverse soft tissue reaction to particulate debris than patients in higher BMI classes. Obese 
class III patients were more likely to be revised for infection (table 8). None of these effect 
sizes is large enough to account for the overall patterns observed. 
Sensitivity analyses 
 
Likelihood ratio tests demonstrated that there was no interaction between BMI and age for 
either revision or mortality. Analyses performed using a competing risks framework did not 
alter the interpretation of any of the analyses reported (table 9, figure 6). Also, cubic spline 
models suggested the same outcomes (figures 7-8). Exclusion of operations before 2007 gave 
the same results as the main analysis (appendix tables 1-4). 
 
 
Discussion 
 
Our results demonstrate that long-term revision rates following primary THR are similar for 
normal and overweight individuals, but they are higher for obese class I, II and III (BMI30 
kg/m2) patients. Despite this, the revision rates of obese class III patients remain acceptable 
by contemporary standards, exceeding the level required for a 10A rating by the Orthopaedic 
Data Evaluation Panel in the UK29. The lowest revision rates were observed in the 
underweight group but the numbers were small, and may be a chance observation. We 
observed a higher risk of 90-day mortality in underweight patients with rates twice as high as 
normal BMI patients. The rates in overweight and obese class I and II patients were 
significantly lower than normal BMI individuals. Lower mortality rates were observed in 
obese class III, but again the numbers were small. 
There is little research of the influence of BMI on the long-term revision risk following 
primary THR. Previous studies have used small cohorts and grouped BMI rather than using 
the WHO classification10-16. Analyses have been restricted to particular implants11,14, 
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considered BMI as a continuous variable10 or only offered short-term follow-up10-12,16. 
Contrary to our findings, a number of studies have found no association between BMI and 
revision14,15. These include a single-centre study of 3,290 patients showing no association 
between obesity and revision risk at a minimum follow-up of 2-years16; the only association 
seen was between morbid obesity and the risk of infection. Although we observed a higher 
proportion of obese class III patients revised for infection, this difference was not sufficient 
to account for the overall patterns observed. A regional registry study of 27,571 THRs found 
no difference in revision rates according to BMI, but did show a weight of greater than 80 
kilograms was predictive of revision13. This finding, limited to men for one indication for 
revision, is of limited generalisability. In a larger study of 63,132 THRs, a 66% higher rate of 
revision in morbidly obese compared to those with normal weight was observed, higher than 
the difference observed in our study10. A previous study based on a cohort of 5,357 patients 
in the NJR at a maximum follow-up of 2-years found higher revision rates in the different 
categories of overweight and obese patients but none of these findings were significant12. In a 
larger NJR analysis of 17,166 patients receiving one type of THR for whom BMI data were 
available, a higher rate of revision was observed when patients with a BMI of >30 kg/m2 
were compared to patients with a lower BMI11. 
Our group has previously observed a protective effect of being overweight when the risk of 
mortality following primary THR is considered4. In the current study, we observed a 
significantly lower risk of mortality in overweight and obese class I and II patients but no 
significant difference between obese class III patients and those with normal BMI. The 
highest rates of mortality were observed in the underweight group. This protective effect of 
increasing BMI was also seen in a single centre study of 756 primary THRs, although non- 
standard groupings were used and the findings were not significant23. Data from the Danish 
registries demonstrated significantly higher mortality in underweight and normal BMI 
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patients compared to overweight patients and suggested a BMI of 27-28 kg/m2 was 
associated with the lowest risk of mortality22. In contrast with these findings and our own 
study, analysis of USA registers and a single center study of 1,744 patients in the UK 
observed no significant association between BMI and the risk of mortality17-21. 
The “obesity paradox”, whereby being overweight or obese offers a protective effect against 
adverse outcomes or mortality, has been observed in cardiac30,31, oncology32 and surgical 
fields33. There is a risk of bias when considering the influence of BMI on outcomes such as 
mortality, the risk of collider bias through mediators such as diabetes does not explain the 
observation, and alternative causative explanations require further investigation34. Although 
those that are underweight may have comorbidities or other illnesses to explain their low 
BMI, the population considered is screened for fitness to undergo surgery, the “healthy 
patient selection effect”, and therefore we do not believe illness in the underweight group 
explains the higher mortality, particularly as our models adjust for ASA grade. Smoking is a 
potential confounding factor that has been identified in patients with cardiovascular disease 
that may at least partially explain the observed mortality patterns and requires further 
investigation35. 
The current study has significant strengths. 1) This is the largest cohort we are aware of with 
complete BMI data analysed to date. 2) Patients were not restricted by demographic or 
prosthesis, for example, all patients that had a resurfacing hip replacement were included as 
they could have conceivably received a THR. 3) Follow up time for revision was 
substantially longer than currently reported, and is informative for obese patients with respect 
to the longevity of THR. 4) Consistent with our previous work, mortality was restricted to 90 
days following surgery, at which point the risk returns to baseline4. 
The study does have limitations. The outcomes are limited to revision and mortality. These 
are commonly used criteria when assessing the outcome following THR but other outcomes 
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such as pain36 and function measured by PROMS, or adverse events37 may be important. We 
did not adjust for co-morbidities, for example coronary heart disease or diabetes, due to lack 
of available data. However, the risk of inducing bias, as co-morbidities may lie on the causal 
pathway between BMI and the outcome of interest, by such a strategy mitigates this 
limitation38. BMI is measured on a single occasion prior to surgery, we were therefore not 
able to investigate effect of BMI trajectories on revision. Due to the relatively short mortality 
window (90 days), we do not believe BMI is likely to change appreciably in this short 
interval. BMI completeness prior to 2007 is poor and patients with BMI in excess of 60 
kg/m2 were excluded. However, we assume the reason for missingness is unrelated to the 
outcomes of interest, and under the Missing At Random statistical assumption39, therefore 
unbiased results will be obtained. Sensitivity analyses restricting data to post 2007 illustrates 
results are unchanged. Our analysis is based on observational data and attributing causation is 
difficult. 
We have analysed data from a large and generalisable prospective national cohort and 
demonstrated that the current trend towards the restriction of access to THR on the basis of 
BMI is not justified when the outcomes of revision and mortality are considered. Whilst 
surgeons, patients and other stakeholders need to be aware of the individual risk profiles 
associated with BMI and interventions such as THR, in order to make fully informed 
decisions, we have shown that the revision and mortality rates are acceptable by 
contemporary standards. We found no evidence to suggest that access to THR should be 
restricted on the basis of BMI for patients with a BMI between 10 and 60 kg/m2. 
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Figure Legends 
 
Figure 1. Flow diagram of patient selection to investigate revision and mortality. THR for 
Trauma included the following indications included on different versions of the NJR 
Minimum Dataset forms: acute-neck of femur, fractured neck of femur, failed 
hemiarthroplasty, chronic trauma, failed internal fixation, unspecified previous hip trauma or 
other hip trauma. 
Figure 2. Cumulative probability of revision up to 11-years after primary THR. The number at 
risk shown at 0, 3, 5, 7, 10 and 11 years following primary THR. Cumulative probabilities have 
been multiplied by 100, shown in percentages (%). 
Figure 3. Cumulative probability of revision with 95% C.I. up to 11-years after the primary 
THR, by BMI classification. Cumulative probabilities have been multiplied by 100, shown in 
percentages (%). 
Figure 4. Cumulative probability of death up to 90-days after primary THR. The number at 
risk shown at 0, 30, 60 and 90 days. Cumulative probabilities have been multiplied by 100, 
shown in percentages (%). 
Figure 5. Cumulative probability of death with 95% C.I. up to 90 days after the primary 
THR, by BMI classification. Cumulative probabilities have been multiplied by 100, shown in 
percentages (%). 
Figure 6. Cumulative incidence function of revision up to 11-years after primary THR. 
Adjusting for the competing risk of death separately for each BMI classification. 415,598 
primary THR were included in the analysis. 
Figure 7. Revision hazard ratio with BMI for RM4 and cubic spline model with 95% C.I. 
The cubic spline model adjusts for the same confounders as RM4. 
Figure 8. Mortality hazard ratio with BMI for RM4 and cubic spline model with 95% C.I. 
The cubic spline model adjusts for the same confounders as MM4. 
